Yemaachi and Institut Pasteur Tunis Forge Oncogenetics Partnership to Sequence and Characterise Inflammatory Breast Cancer in Patients of African Descent
Partnership is emblematic of a global effort to characterise cancer development and progression in individuals of African descent, who have traditionally been excluded from genomic oncology studies and clinical trials 22nd October 2024, Tunis, Tunisia — Precision oncology company Yemaachi Biotech and Institut Pasteur Tunis today announced a research partnership investigating genomics in inflammatory breast […]
Yemaachi Biotech, Lucence Aim to Improve Genomic Breast Cancer Testing in Ghana and Beyond
GenomeWeb covers Yemaachi’s collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access
PALO ALTO, Calif. & ACCRA, Ghana–(BUSINESS WIRE)–Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.